Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.
Ahmed A KolkailahIldiko LingvayIdit Dobrecky-MeryAlona AharonovichJens-Peter DavidCecilie HolseSøren RasmussenDarren K McGuirePublished in: Diabetes, obesity & metabolism (2022)
Keyphrases
- coronary artery disease
- cardiovascular disease
- cardiovascular events
- study protocol
- phase iii
- clinical trial
- percutaneous coronary intervention
- phase ii
- type diabetes
- coronary artery bypass grafting
- randomized controlled trial
- heart failure
- skeletal muscle
- adipose tissue
- acute coronary syndrome
- metabolic syndrome
- aortic stenosis